-
Innovation Ranking
Innovation Ranking – Lu Zhou Lao Jiao Co Ltd
Lu Zhou Lao Jiao Co Ltd (Luzhou Laojiao) carries out the manufacturing and distribution of liquor products. The company provides alcoholic beverages including beer, wines and gift sets. Its products include the National Cellar 1573 series and Luzhou Lao Jiao Te Qu series spirits. Luzhou Laojiao markets its products under the brand names Luzhou Laojiao Jiaoling Baijiu, Luzhou Laojiao Touqu, Luzhou Laojiao Health Care Baijiu, Luzhou Laojiao Erqu, and Luzhou Laojiao Multi-mixed Cocktail. It distributes its products in different parts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Dotatate in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Dotatate in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Dotatate in Neuroblastoma Drug Details: Lutetium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Dotatate in Pheochromocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Dotatate in Pheochromocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Dotatate in Pheochromocytoma Drug Details: Lutetium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Dotatate in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Dotatate in Neuroendocrine Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Dotatate in Neuroendocrine Tumors Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Edotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Edotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Edotreotide in Neuroendocrine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Oxodotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Oxodotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Oxodotreotide in Neuroendocrine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Vipivotide Tetraxetan in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Vipivotide Tetraxetan in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Vipivotide Tetraxetan...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – [177Lu]Lu-rhPSMA-10.1 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - [177Lu]Lu-rhPSMA-10.1 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. [177Lu]Lu-rhPSMA-10.1 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...